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Background: Non–small-cell lung cancer (NSCLC) has a signifi-
cant impact on patients’ health-related quality of life (HRQOL). 
This study aimed to measure health state utility values representing 
the individual’s preferences for specific health-related outcomes in 
advanced NSCLC patients and to assess predictive parameters.
Methods: We conducted a prospective quality-of-life survey on 
advanced NSCLC patients in 25 hospitals in Europe, Canada, 
Australia, and Turkey. HRQOL was assessed using the EuroQol 
(EQ-5D) questionnaire and EQ-5D utility and EQ-visual analog 
(EQ-VAS) scores were estimated.
Results: Three hundred nineteen patients were recruited of which 263 
had evaluable data. Mean utility for progression-free (PF) patients on 
first-, second-, and third-/fourth-line treatment was 0.71 (SD = 0.24), 
0.74 (SD = 0.18), and 0.62 (SD = 0.29), respectively. Mean utility for 
patients with progressive disease (PD) while on first-, second- and 
third-/fourth-line treatment was 0.67 (SD = 0.2), 0.59 (SD = 0.34), 
and 0.46 (SD = 0.38), respectively. Overall, patients with PD had 
lower mean utility scores than PF patients (0.58 versus 0.70). The 
results of the EQ-VAS showed that the score decreased with later 
treatment lines. Patients with PD had a 10-point decrease in VAS 
scores compared with PF patients (53.7 versus 66.6). The regression 
analysis revealed that stage IV disease, higher lines of treatment, and 
health state were significant predictors of utility at the 10% level.
Conclusion: The results presented indicate a substantial impact 
of lung cancer on patients’ HRQOL, with stage IV disease, line of 
treatment, and PD, resulting in considerable deterioration of utility. 
The values obtained here will inform evaluations of cost-utility for 
NSCLC therapies.
Key Words: Health-related quality of life, EuroQol-5D, Non–small-
cell lung cancer, Health state utility value.
(J Thorac Oncol. 2013;8: 997-1003)
Non–small-cell lung cancer (NSCLC) is the leading cause of cancer death globally, with 1.37 million deaths each 
year.1 With only 1% to 5% overall 5-year survival rate for 
stage IIIb/IV NSCLC, the treatment of this disease remains a 
major clinical and public health challenge.2
NSCLC has a significant impact on patients’ health-
related quality of life (HRQOL), wellbeing, and family 
functioning.3 The impact of NSCLC on physical HRQOL is 
related to symptoms such as persistent cough, dyspnea, and 
chest pain.4 Patients with metastatic disease also often present 
with anorexia, fatigue, and weight loss. Physical functioning 
is usually impaired as a result of the symptoms, and diagnosis 
and treatment may lead to impaired psychological function.5,6 
Along with efficacy and safety outcomes, patient-reported 
outcomes and HRQOL have emerged as primary treatment 
goals in their own right.7 Furthermore, HRQOL in routine-
care patients provides a subjective measure of symptom 
severity, which complements clinician scoring in predicting 
overall survival.8 As the use of economic evaluation increases 
globally, quality-adjusted life-years and utility assessments are 
being used as a key outcome measure within those evaluations.
Copyright © 2013 by the International Association for the Study of Lung 
Cancer
ISSN: 1556-0864/13/0808-0997
Health-Related Quality of Life and Utility in Patients  
with Advanced Non–Small-Cell Lung Cancer
A Prospective Cross-Sectional Patient Survey  
in a Real-World Setting
Christos Chouaid, MD, PhD,* Jason Agulnik, MD,† Erdem Goker, MD,‡  
Gerarda J.M. Herder, MD,§ Jason F. Lester, MD,║ Johann Vansteenkiste, MD, PhD,¶  
Henrik W. Finnern, MSc,# Juliane Lungershausen, MSc,** Jennifer Eriksson, MSc,††  
Kun Kim, MSc,†† and Paul L.R. Mitchell, MD, PhD‡‡
*Service de Pneumologie, Centre Hospitalier Intercommunal Créteil, Paris, 
France; †Division of Pulmonary Diseases, Department of Medicine, Jewish 
General Hospital, Montreal, Quebec, Canada; ‡Department of Medical 
Oncology, Ege University, Izmir, Turkey; §Department of Pulmonary 
Diseases, St. Antonius Ziekenhuis, Nieuwegein, The Netherlands; 
║Oncology, Velindre Hospital, Cardiff, Wales, United Kingdom; 
¶Respiratory Oncology Unit (Pulmonology), University Hospital 
Leuven, Leuven, Belgium; #Boehringer-Ingelheim Pharmaceuticals 
Inc., Ingelheim am Rhein, Germany; **Boehringer-Ingelheim GmbH, 
Ingelheim, Germany; ††OptumInsight Life Sciences, Stockholm, Sweden; 
and ‡‡Department of Medical Oncology, Olivia Newton-John Cancer and 
Wellness Centre, Austin Health, Victoria, Australia.
Disclosure: Juliane Lungershausen is employed at Boehringer-Ingelheim 
GmbH and HenrikFinnern at Boehringer-Ingelheim Pharmaceuticals Inc. 
Jennifer Eriksson and Kun Kim are employed at OptumInsight, a research 
organization acting as consultants to the pharmaceutical industry. The 
other authors declare no conflict of interest.
Address for correspondence: Christos Chouaid, MD, PhD, Service de 
Pneumologie et Pathologie Professionnelle, CHI Créteil—40 avenue de 
Verdun, 94010 Creteil Cedex, France. E-mail: christos.chouaid@chicreteil.fr
ORIGINAL ARTICLE
998 Copyright © 2013 by the International Association for the Study of Lung Cancer
Chouaid et al. Journal of Thoracic Oncology ®  •  Volume 8, Number 8, August 2013
Both generic and disease-specific quality-of-life instru-
ments are available. Disease-specific instruments, such as 
the cancer-specific European Organisation for Research and 
Treatment of Cancer Quality of Life Questionnaire (QLQ)-Core 
30 Items (C30), will not allow comparison of quality-of-life 
scores across diseases and will not allow estimation of sum-
mary scores, which is possible when assessing quality of life 
with the disease-generic EuroQol (EQ-5D) questionnaire.9 The 
EQ-5D is a generic HRQOL measure that comprises the EQ-5D 
and EQ-visual analog scale (VAS). The EQ-5D measures five 
dimensions of health (mobility, self-care, usual activities, pain/
discomfort, anxiety/depression) within three levels of severity 
(no/some/extreme problems). The EQ-VAS records the respon-
dents’ self-rated health status on a vertical graduated (0–100) 
VAS.10,11 The overall HRQOL described by the EQ-5D can be 
used to derive utility values between 0 (dead) and 1 (full health).12
Several studies13 have already investigated HRQOL in a 
clinical trial setting using disease-specific instruments, but few 
studies have investigated the impact of NSCLC on HRQOL 
measured with generic instruments and in settings outside of 
clinical trials of therapeutic interventions.14–18 Predictors for 
utility values have thus far only been assessed in the general 
population,15,17,18 or clinical trial populations.19
The objectives of this study were to measure health state 
utility values in advanced NSCLC patients, and to assess fac-
tors that predict health state utility values.
PATIENTS AND METHODS
This patient survey was designed as a multicountry, mul-
tisite, cross-sectional study of patients 18 years and older, who 
have previously been diagnosed with advanced NSCLC (stage 
IIIB/IV). Patients were enrolled prospectively at a total of 25 
sites in Australia, Belgium, Canada, France, Italy, Turkey, The 
Netherlands, Sweden, and the United Kingdom. The study 
was approved by the ethics committees in the respective coun-
tries, and patient-informed consent was obtained.
Patients were included if they had an Eastern Cooperative 
Oncology Group performance status of 0 to 2, and were aged 
18 years or older. Patients should have been receiving first-, 
second-, or third-/fourth-line pharmacotherapy or best sup-
portive care (BSC; BSC patients were required to have failed 
at least 2 lines of pharmacotherapy) and had to have received 
two cycles of their current pharmacotherapy (equivalent to 
6–8 weeks ±3 days of therapy) or equivalent duration of BSC. 
Patients who had been involved in clinical trials investigating 
monotherapy or combination therapy, which had not received 
regulatory approval in NSCLC, were not allowed in the 
study. Likewise, patients receiving first-, second-, or third-/
fourth-line pharmacotherapy, who were aware of their tumor 
response status to current therapy before completing the 
EQ-5D and EQ-VAS questionnaires, were deemed unsuitable 
for participation, as that knowledge may have influenced their 
perceived health status. Patients were enrolled in the patient 
survey between April 2010 and August 2011.
All eligible patients were recruited in sequence by their 
treating physician. Sites were instructed to enroll patients with 
an equal distribution in all treatment lines and BSC. The EQ-5D 
and the EQ-VAS were administered to patients who completed 
the questionnaires at the study site and returned the question-
naires to the physician or the study nurse. In addition, the 
physician or study nurse completed a questionnaire with infor-
mation on the patient’s past and current treatment and response 
to the actual treatment line (carried out by the physician using 
Response Evaluation Criteria in Solid Tumors criteria).The 
quality-of-life scores in the EQ-5D were transformed into util-
ity values by using modeling valuations developed by Dolan et 
al.12 with EQ-5D value weights elicited from a U. K. population.
Health States
Patients were stratified into predefined health states 
according to line of therapy and disease status (progression-
free [PF]/progressive disease [PD]). There was no specific 
question in the survey asking which line of treatment the 
patient was currently undergoing, consequently, the line of 
treatment variable was derived from information on the num-
ber of previous lines received. As per the inclusion criteria, 
all patients were receiving their second cycle of each respec-
tive line of treatment, defined as 6 to 8 weeks from initia-
tion of their line of treatment ± 3 days, when responding to 
the EQ-5D questionnaire. At this time point, patients were 
unaware of their tumor response status but were told about the 
result at a later time point.
Differences in utility values were considered clinically 
relevant for differences of 0.074 utility units based on a previ-
ous study.20
Determinants of Utility
The determinants of utility were investigated with a mul-
tiple linear regression model. Using the EQ-5D derived util-
ity values, the following covariates were included in the full 
model: age at metastatic diagnosis, sex (men versus women), 
current stage (stage IV versus IIIb), histology (adenocarci-
noma versus others), smoking history (current/ever-smoker 
versus never-smoker), Charlson Comorbidity Index, occur-
rence of severe adverse event (grade 3/4 to have occurred 
during current line of treatment/BSC), oral drug (oral versus 
intravenous), dose reduction (dose reduced for any drug in the 
regimen versus dose not reduced), and health state and region 
(Canada versus Northern Europe [The Netherlands, Belgium, 
United Kingdom, Sweden] versus Southern Europe [France, 
Italy] versus Australia). The regression model required com-
plete information on all variables of patients, consequently, 
the model was run on the subset of the patients who had com-
plete information on line of treatment and response status. 
The model was tested for heteroskedasticity and normality of 
residuals. Insignificant covariates were removed with back-
ward elimination, and the model was rerun, until all covariates 
were significant at a 10% level.
Statistical significance was evaluated at the 5% level. 
All p values reported are two-sided. Analyses were performed 
using SAS (version 9.2; SAS, Cary, NC).
RESULTS
A total of 319 patients were enrolled in the study, of 
which 56 were excluded—stage was missing for one patient, 
one patient died before completing the EQ-5D questionnaire, 
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nine BSC patients had not had at least two previous lines of 
therapy, and 45 patients did not complete the EQ-5D ques-
tionnaire. None of the patients from Turkey were eligible.
Patient Characteristics
Mean age at diagnosis was 64.7 years (SD = 10.1). One 
hundred sixty-one patients (61.2%) were men, 219 patients 
(83.3%) were exsmokers or current smokers, whereas 41 
patients (15.6%) had never smoked (Table 1). At the time the 
survey was completed, 17.9% of patients had stage IIIB and 
82.1% stage IV NSCLC. The patients diagnosed with adeno-
carcinoma were 66.2% followed by 17.1% with squamous cell 
carcinoma.
The mean utility value in the pooled patient sample 
was 0.66 (SD = 0.29). Results by health state are presented 
in Table 2. Patients on first-, second-, and third-/fourth-line 
treatment who were PF had a mean utility score of 0.71 (SD = 
0.24), 0.74 (SD = 0.18), and 0.62 (SD = 0.29), respectively. 
Patients who were reported to have PD had a mean utility 
value of 0.67 (SD = 0.20) if they were on first-line treatment, 
0.59 (SD = 0.34) if they were on second-line treatment, and 
0.46 (SD = 0.38) if they were on third-/fourth-line treatment. 
Utility values for patients on BSC were considered nonevalu-
able because of the low patient sample. Patients with PD had 
a lower utility compared with PF patients (0.58 [SD = 0.32] 
versus 0.70 [SD = 0.25]).
A sensitivity analysis using Belgian utility weights was 
also conducted. Estimating utility values using the Belgian 
weights resulted in a mean utility value of 0.64 (SD = 0.24), 
and thus, a difference in mean utility of 0.02 compared with 
the utility value based on U. K. weights (mean = 0.66). The 
difference (using a t test with unequal variances) was not sta-
tistically significant (p = 0.3371), moreover, this difference in 
utility was also not clinically meaningful.
The regression model was run on 243 patients who had 
complete information on all covariates as shown in Table 3 
(6 patients without complete information on line of treatment 
and response status and 6 patients belonging to BSC group 
were excluded). The regression analysis revealed that stage IV 
disease, health state, and higher lines of treatment were sig-
nificant predictors of utility at the 10% level.
Keeping all assumptions unchanged, we found that 
patients presenting with stage IV disease had a negative 
reduction in utility (−0.07) compared with patients with stage 
IIIB disease.
As expected, there was a trend toward PD having a 
negative impact on utility, when first-line PF health status 
was referenced, which reached significance at the 10% level 
for patients in third-/fourth-line treatment. Also, later line of 
treatment had a larger negative impact on utility (−0.10 for 
third-/fourth-line treatment PF, and −0.26 for third-/fourth-
line treatment PD).
Across all patients, the majority of patients (56%) 
reported no difficulty in mobility (Table 4). Mobility difficul-
ties were similar in patients on first-line treatment who were 
PF, in patients with PD, and in patients on third-/fourth-line 
treatment and PF, with difficulties reported by 43 (37%), 10 
(38%), and 9 (36%) patients, respectively. A slightly higher 
proportion of PF patients on second-line treatment reported 
some mobility difficulties. For patients with Pd in second-- 
and third-/fourth-line treatment, 8 (47%) and 12 (57%) 
patients reported some difficulty with mobility, respectively.
A similar pattern was demonstrated in the self-care 
domain. Overall, 206 patients (78%) reported no difficulties 
with self-care. A higher proportion of patients with PD 
reported some difficulties with self-care, and 27%, 24%, and 
48% patients in first-, second- and third-/fourth-line treatment, 
respectively, reported some difficulties or that they were 
unable to wash and dress themselves. An increased proportion 
of PF patients on third-/fourth-line treatment reported some 
difficulties with self-care (28%).
TABLE 1.  Patient and Disease Characteristics
n = 263 (100%)
Sex, n (%)
 Male 161 (61.2%)
Smoking history, n (%)
 Never-smoker 41 (15.6%)
 Current/ever-smoker 219 (83.3%)
 Not available/missing 3 (1.1%)
Age at advanced-stage diagnosis, yr
 Mean (SD) 64.8 (10.1)
 Minimum, maximum 32.8, 99.6
 95% CI 63.5; 66.0
Clinical stage at first diagnosis, n (%)
 Ia–IIIa 30 (11.4%)
 IIIb 44 (16.7%)
 IV 156 (59.3%)
 Not available/missing 33 (12.6%)
Clinical stage at time of survey, n (%)
 IIIb 47 (17.9%)
 IV 216 (82.1%)
Histology, n (%)
 Large-cell carcinoma 18 (6.8%)
 Adenocarcinoma 174 (65.2%)
 Squamous cell carcinoma 45 (17.1%)
 Other 26 (9.9%)
Charlson Comorbidity Index
 Mean (SD) 6.45 (0.9)
 Minimum, maximum 6.0, 12.0.
 95% CI 6.3; 6.6
Line of treatment, n (%)
 First- 145 (55.1%)
 Second- 65 (24.7%)
 Third/fourth- 47 (17.9%)
 BSC 6 (2.3%)
Disease statusa, n (%)
 Progression-free 190 (72.2%)
 Progressive disease 64 (24.3%)
aResponse status was not collected for patients on BSC, but was still reported for 
n = 3 patients.
SD, standard deviation; BSC, best supportive care; CI, confidence interval.
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Overall, 121 patients (46%) reported some difficulties 
with usual activities. The proportion of PF patients on first- 
and second-line treatment reporting some difficulties with, 
or inability to, perform usual activities was similar, 58 (50%) 
and 24 (51%), respectively, whereas, a higher proportion was 
observed for patients on third-/fourth-line treatment with 
64%. Having PD had a substantial impact on usual activities; 
73%, 76%, and 62% of patients in first-, second- and third-/
fourth-line treatment, respectively, reported some difficulties 
with or were unable to perform usual activities.
Presence of pain and/or discomfort had the highest 
frequency in all five domains, with patients reporting either 
moderate 151 (57%) or extreme 16 (6%) pain or discomfort. 
Seventy PF patients (61%) on first-line treatment reported 
moderate or extreme pain. Results were similar among PF 
patients on second-line and third-/fourth-line treatment, with 
25 patients (53%) and 18 patients (72%) reporting moderate 
or extreme pain, respectively. The highest frequency of mod-
erate or extreme pain was reported in first-, second- and third-/
fourth-line treatment by 77%, 59%, and 71%, respectively, for 
patients with PD.
For the anxiety domain, 139 patients (53%) reported that 
they were not anxious or depressed, whereas, 43% reported 
to be moderately anxious or depressed; 40%, 53%, 44% of 
PF patients on first-, second- and third-/fourth-line treatment, 
respectively, reported to be moderately or extremely anxious 
or depressed. For patients with PD, the figures were 54%, 
35%, and 62% in the first-, second- and third-/fourth-line 
treatment, respectively.
VAS scores are presented in Table 2. PF patients on first-, 
second-, and third-/fourth-line treatment reported a mean VAS 
score of 69.3 (SD = 18.3),65.0 (SD = 19.6), and 60.8 (SD = 
21.5), respectively, whereas patients with PD in first-, second-, 
and third-/fourth-line reported a mean VAS score of 58.7 (SD = 
17.4), 53.5 (SD = 23.3), and 48.2 (SD = 21.9), respectively. 
Overall, patients with PD had a 10-point decrease in VAS 
score compared with those who were PF: 53.7 (SD = 20.8) 
versus 66.6 (SD = 19.9) (Table 2).
DISCUSSION
In this study, HRQOL and utility values in patients with 
advanced NSCLC were studied. HRQOL, as measured by the 
EQ-5D domains, and utility were lower in patients with PD 
when compared with PF patients.
The analysis of utility values by health state revealed a 
clear decrease in utility for patients with PD compared with 
PF patients. Moreover, utility for PD patients decreased with 
higher lines of treatment. These results were expected factor-
ing in the negative effect of PD and higher line of treatment. 
Comparing of the utility in PF patients on first-line treatment 
with PF patients on second-line treatment resulted in a slightly 
higher but not clinically relevant mean utility in patients on 
second-line treatment. One potential explanation for this could 
be that patients who move on to a higher line of treatment com-
prise a subset that is relatively fit. Conversely, PF patients on 
third-/fourth-line treatment had a clinically relevant decline in 
utility compared with patients on first-line treatment.
TABLE 2.  Calculated Utility Values and VAS Score by HS, PF, and PD
HS Utility Values Mean (SD); 95% CI EQ-VAS Score Mean (SD); 95% CI
All patients (N = 263) 255a 0.66 (0.29) [0.62–0.69] 257b 63.05 (20.89) [60.5–65.6]
HS1: first-line PF (n = 115) 111 0.71 (0.24) [0.67–0.76] 112 69.31 (18.33) [65.9–72.8]
HS2: first-line PD (n = 26) 26 0.67 (0.2) [0.59–0.75] 24 58.67 (17.4) [51.3–66.0]
HS3: second-line PF (n = 47) 44 0.74 (0.18) [0.68–0.80] 47 65.00 (19.6) [59.2–70.8]
HS4: second-line PD (n = 17) 17 0.59 (0.34) [0.42–0.77] 17 53.47 (23.25) [41.5–65.4]
HS5: third/fourth-line PF (n = 25) 24 0.62 (0.29) [0.49–0.74] 24 60.79 (21.5) [51.7–69.9]
HS6: third/fourth-line PD (n = 21) 21 0.46 (0.38) [0.28–0.63] 21 48.24 (21.86) [38.3–58.2]
HS7: BSC (n = 6) 6 NEc 6 NEc
PF (n = 190) 182d 0.70 (0.25) [0.66–0.73] 186e 66.64 (19.88) [63.8–69.5]
PD (n = 64) 64f 0.58 (0.32) [0.50–0.66] 62g 53.71 (20.80) [48.4–59.0]
aSum of HS1–7 and six patients not classified to an HS. Eight patients had missing values on at least one of the EQ-5D questions, thus, a utility score was not calculated.
bSum of HS1–7 and six patients not classified to an HS. Six patients had missing values to the VAS scale.
cNot evaluable. Patient sample was considered too small for a meaningful analysis.
dSum of HS2, HS4, and HS6.
eSum of HS1, HS3, HS5, and three patients in HS7.
fSum of HS1, HS3, HS5, and three patients in HS7.
gSum of HS2, HS4, and HS6.
VAS, Visual Analog Scale; PD, progressive disease; Ci, confidence interval; HS, health state; PF, progression-free; EQ, EuroQol; Qol, quality of life.
TABLE 3.  Drivers of Utility (HS, PF, and PD)
Covariate Parameter Estimate SE p
Intercept 0.77 0.03 <0.0001
Stage IV −0.07 0.04 0.029
HS 1: first-line PFa 0.00 NA NA
HS 2: first-line PD −0.04 0.04 0.4067
HS 3: second-line PF 0.03 0.04 0.4697
HS 4: second-line PD −0.11 0.08 0.1836
HS 5: third/fourth-line PF −0.10 0.06 0.0920
HS 6: third/fourth-line PD −0.26 0.08 0.0022
aHS1 is reference category.
HS, health state; SE, standard error; PD, progressive disease; PF, progression-free; 
NA, not available.
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The regression analysis revealed that stage IV disease, 
line of therapy, and health state were significant predictors of 
utility. As expected there were trends toward reduced utility for 
stage IV disease and PD, the latter reaching significance for 
third-/fourth-line progressive health state. A significant reduc-
tion in utility for higher lines of treatment was also apparent.
Mobility difficulties increased with line of treatment, 
and were more often reported among patients with PD. Some 
TABLE 4.  Health-Related Quality of Life (EuroQol-5D Domains)
Domain Line of Treatment Level Progression-Free % Progression %
Mobility First-line No difficulties 60.9 61.5
Some difficulties 37.4 38.5
Extreme difficulties 1.7 0.0
Second-line No difficulties 55.3 47.1
Some difficulties 44.7 47.1
Extreme difficulties 0.0 5.9
Third/fourth-line No difficulties 60.0 33.3
Some difficulties 36.0 57.1
Extreme difficulties 4.0 9.5
Self-care First-line No difficulties 85.2 73.1
Some difficulties 13.0 26.9
Extreme difficulties 1.7 0.0
Second-line No difficulties 83.0 76.5
Some difficulties 17.0 11.8
Extreme difficulties 0.0 11.8
Third/fourth-line No difficulties 72.0 52.4
Some difficulties 24.0 33.3
Extreme difficulties 4.0 14.3
Usual activities First-line No difficulties 49.6 26.9
Some difficulties 42.6 65.4
Extreme difficulties 7.8 7.7
Second-line No difficulties 46.8 23.5
Some difficulties 48.9 58.8
Extreme difficulties 2.1 17.6
Third/fourth-line No difficulties 36.0 38.1
Some difficulties 40.0 38.1
Extreme difficulties 24.0 23.8
Pain First-line No difficulties 35.7 23.1
Some difficulties 55.7 76.9
Extreme difficulties 5.2 0.0
Second-line No difficulties 42.6 41.2
Some difficulties 51.1 47.1
Extreme difficulties 2.1 11.8
Third/fourth-line No difficulties 28.0 28.6
Some difficulties 68.0 52.4
Extreme difficulties 4.0 19.0
Anxiety First-line No difficulties 59.1 46.2
Some difficulties 39.1 50.0
Extreme difficulties 0.9 3.8
Second-line No difficulties 46.8 64.7
Some difficulties 51.1 35.3
Extreme difficulties 2.1 0.0
Third/fourth-line No difficulties 52.0 38.1
Some difficulties 36.0 57.1
Extreme difficulties 8.0 4.8
The following missing values were reported; n = 1 (usual activities domain), n = 6 (pain domain), n = 2 (anxiety domain).
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or extreme difficulties were most often reported in the pain 
and usual activities domains of the EQ-5D. Furthermore, a 
higher proportion of patients with PD consistently reported 
some or extreme difficulties compared with PF patients across 
all dimensions, except for the anxiety dimension, indicat-
ing a heavier burden in HRQOL in PD patients. The result 
of the anxiety domain showed no clear pattern, which may 
be because patients at the time of survey completion did not 
know their tumor response status.
The EQ-VAS scores showed a similar trend as the calcu-
lated utility values with lower VAS score for PD patients com-
pared with PF patients. However, PF patients on second-line 
treatment had a lower VAS score than PF patients on first-line 
treatment, indicating the impact on the results of using differ-
ent elicitation instruments.
PF patients included in this study were estimated to 
have a utility value of 0.71 (first-line treatment), 0.73 (second-
line treatment), and 0.62 (third/fourth line-treatment). This 
is somewhat higher than what has been reported previously. 
Doyle et al.15 assessed preferences for metastatic NSCLC 
health state descriptions, which aimed to contrast disease 
state and impact of specific severe adverse events. One hun-
dred one members of the general public assessed their pref-
erence for each health state in a standard gamble interview 
and on a VAS. Stable disease with no additional symptoms 
resulted in a utility value of 0.626, which declined by 0.069 
with the addition of pain, 0.050 for dyspnea, and 0.046 for 
cough. Similarly, Nafees et al.17 reported utility values (based 
on standard gamble techniques) for stable disease to be 0.653. 
These differences in results may be because of the elicita-
tion method, the difference in study population (patients ver-
sus general public), or a combination of both. Moreover, in 
a multicenter, cross-sectional study of 95 NSCLC patients, 
Trippoli et al.18 showed that in comparison with data previ-
ously reported for healthy individuals, patients with NSCLC 
scored 8% to 73% lower on all eight domains of the SF-36 
and showed a mean relative reduction in utility values of 
26%, as measured with the EQ-5D. The EQ-5D question-
naire resulted in a mean utility value of 0.58. The presence of 
metastases was found to have the greatest impact on HRQOL 
(a decline of 0.236). The negative impact of disease progres-
sion and presence of metastases has been reported in other 
studies.15,17,18 However, the authors did not collect information 
on disease stage, which makes a direct comparison of results 
with our study difficult.
One strength of this study was the population analyzed, 
which was a large sample of patients treated for advanced 
NSCLC recruited across Europe, Canada, Turkey, and 
Australia. In addition, the observational data are an appropri-
ate method to provide outcomes from a representative patients 
sample complementing data collected from patients in the 
clinical trial setting.
Limitations include the potential risk of selection bias 
in recruiting patients in the study such that the patients who 
accepted the invitation to participate were possibly more resil-
ient than the patients who refused participation. Moreover, 
the estimated utility values calculated on the basis of EQ-5D 
might be overestimated compared with time tradeoff methods, 
considering that some disease consequences (e.g., dyspnea) 
may not significantly impact on some of the EQ-5D dimen-
sions, such as mobility and self-care. The EQ-5D question-
naire may, thus, not be sensitive enough to capture these 
disease consequences. There are major differences in spread 
of utility values for some domains, and future research should 
explore this point to determine whether some domains should 
be used in preference to others.
CONCLUSION
This study indicates a substantial impact of lung cancer 
on patients’ quality of life and health-related utility. The pres-
ence of PD results in considerable deterioration in utility of 
the patients. The results from this study will inform evaluation 
of the cost-utility of NSCLC therapies.
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